



Express Mail. No. **EV 654 849 595 US**
Sheet 1 of 8 of List of References

Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

11183-004-999

APPLICATION NO.

10/754,922

APPLICANT

Stavenhagen et al.

FILING DATE

January 9, 2004

ART UNIT

~~1643~~ 1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
/CC/	A01	2003/0158389	08/21/03	Idusogie et al.	
	A02	2004/0002587	1/1/04	Watkins et al.	
	A03	2004/0110226	6/10/04	Lazar et al.	
	A04	2004/0132101	7/8/04	Lazar et al.	
	A05	2004/0185045	9/23/04	Koenig et al.	
	A06	2005/0054832	3/10/05	Lazar et al.	
	A07	4,752,601	06/21/88	Hahn	
	A08	5,348,876	09/20/94	Michaelson et al.	
	A09	5,576,184	11/19/96	Better et al.	
	A10	5,585,089	12/17/96	Queen et al.	
	A11	5,624,821	4/29/97	Winter et al.	
	A12	5,648,260	07/15/97	Winter et al.	
	A13	5,698,449	12/16/97	Baumann et al.	
	A14	5,723,584	3/3/98	Schatz	
	A15	5,736,135	4/7/98	Goeddel et al.	
	A16	5,736,137	04/07/98	Anderson et al.	
	A17	5,874,239	2/23/99	Schatz	
	A18	5,932,433	8/3/99	Schatz	
	A19	5,985,599	11/16/99	Mckenzie et al.	
	A20	6,025,485	2/15/00	Kamb et al.	
	A21	6,114,147	9/5/00	Frenken et al.	
	A22	6,165,745	12/26/00	Ward et al.	
	A23	6,194,551	2/27/01	Idusogie et al.	
	A24	6,242,195	06/05/01	Idusogie et al.	
	A25	6,277,375	08/21/01	Ward	
	A26	6,300,065	10/9/01	Kieke et al.	
	A27	6,331,391	12/18/01	Wittrup et al.	
	A28	6,423,538	7/23/02	Wittrup et al.	
/CC/	A29	6,455,263	9/24/02	Payan	

EXAMINER /Chun Crowder/ (04/12/2007)

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYJD: 1615621.4

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11183-004-999	10/754,922
	APPLICANT	
	Stavenhagen et al.	
	FILING DATE	ART UNIT
	January 9, 2004	1649 1644

U.S. PATENT DOCUMENTS					
/CC/	A30	6,528,624	03/04/03	Idusogie et al.	
	A31	6,538,124	03/25/03	Idusogie et al.	
	A32	6,737,056	5/18/04	Presta	
/CC/	A33	6,821,505	11/23/04	Ward	

FOREIGN PATENT DOCUMENTS						
		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
/CC/	B01	EP 0 327 378	0809/89	The Trustees of Columbia University		
	B02	WO 88/07089	09/22/88	Medical Research Council		
	B03	WO 89/07142	08/10/89	Morrison, S.		
	B04	WO 92/16562	10/01/92	Lynxvale Limited		
	B05	WO 93/22332	11/11/93	Board of Regents, University of Texas System		
	B06	WO 94/18330	8/18/94	Unilever PLC		
	B07	WO 94/29351	12/22/94	Morgan, S. et al.		
	B08	WO 95/05468	02/23/95	Lynxvale Limited		
	B09	WO 97/28267	08/07/97	Repligen Corporation		
	B10	WO 97/34631	09/25/97	Board of Regents, The University of Texas System		
	B11	WO 97/44362	11/27/97	Protein Design Labs, Inc.		
	B12	WO 98/05787	02/12/98	Bristol-Myers Squibb Company		
	B13	WO 98/23289	06/04/98	The General Hospital Corporation		
	B14	WO 98/52975	11/26/98	Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts	Abstract only	
	B15	WO 99/43713	09/02/99	Lexigen Pharmaceuticals Corporation		
	B16	WO 99/51642	10/14/99	Genentech, Inc		
	B17	WO 99/58572	11/18/99	Cambridge University Technical Services Limited		
	B18	WO 00/09560	02/24/00	Abgenix, Inc.		
/CC/	B19	WO 00/42072	7/20/00	Genenech, Inc.		

EXAMINER /Chun Crowder/ (04/12/2007)	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11183-004-999	10/754,922
	APPLICANT	
	Stavnhagen et al.	
	FILING DATE	ART UNIT
	January 9, 2004	1643 1644

FOREIGN PATENT DOCUMENTS						
/CC/	B20	WO 02/060919	08/0802	Medimmune, Inc.		
	B21	WO 02/086070	10/31/02	Dyax Corporation, Inc.		
	B22	WO 03/074679	09/12/03	Xencor		
	B23	WO 04/029207	04/08/04	Xencor		
	B24	WO 04/074455	09/02/04	Applied Molecular Evolution, Inc.		
	B25	WO 04/099249	11/18/04	Xencor		
	B26	WO 05/070963	08/04/05	Applied Molecular Evolution, Inc.		
/CC/	B27	WO 06/020114	02/23/06	Applied Molecular Evolution, Inc.		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C01	Altman et al., Phenotypic Analysis of Antigen-Specific T Lymphocytes", Science 274:94-96, 1996	
C02	Angal et al., Mol Immunol 30 :105-108, 1993	
C03	Armour et al., Biochemical Society Transactions 30 :495-500, 2002	
C04	Armour et al., Eur J Immunol 29 :2613-2624, 1999	
C05	Armour et al., Mol Immunol 40 :585-593, 2003	
C06	Baggiolini M, Dewald B. Experientia. Oct 15;44(10):841-848, 1988	
C07	Boder and Wittrup, 1997, "Yeast surface display for screening combinatorial polypeptide libraries", Nature Biotechnology 15:553-557	
C08	Boder and Wittrup, Biotechnol Prog 14:55-62, 1998	
C09	Boder and Wittrup, Methods in Enzymology 328:430-444, 2000	
C10	Boder et al., Proc. Natl. Acad. Sci. USA 97:10701-10705, 2000	
C11	Bredius et al., Immunology 83:624-630, 1994	
C12	Brekke et al., Eur J Immunol 24:2542-2547, 1994	
C13	Brown EJ., Vol. 45 (Microbes as Tools for Cell Biology) in <i>Methods In Cell Biololgy</i> , Russell ed. Academic Press Inc. pp.147-64, 1994	
C14	Burlmeister et al., Nature 372:379-383, 1994	
C15	Burton and Woof, Advances in Immunology 51:1-84, 1992	
C16	Burton et al., Mol Immunol 25:1175-1181, 1988	
C17	Burton, Mol Immunol 22:161-206, 1985	
C18	Canfield and Morrison, J Exp Med 173:1483-1491, 1991	
C19	Caron et al., J Exp Med 176 :1191-5, 1992	
C20	Carter et al., Proc. Natl. Acad. Sci. USA 89:4285-4289, 1992	

EXAMINER /Chun Crowder/ (04/12/2007)	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11183-004-999	10/754,922
	APPLICANT	
	Stavnhagen et al.	
	FILING DATE	ART UNIT
	January 9, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C21	Catron et al., Blood 99 :754-758, 2002
C22	Chappel et al., Proc. Natl. Acad. Sci USA 88:9036-9040, 1991
C23	Chappel et al., J Biol. Chem 268:25124-25131, 1993
C24	Ciccimarra et al., PNAS 72 :2081-2083, 1975
C25	Clynes and Ravetch, Immunity 3:21-26, 1995
C26	Clynes et al., J Exp Med 189:179-185
C27	Clynes et al., Nature Medicine 6 :443-446, 2000
C28	Clynes et al., PNAS 95:652-656, 1998
C29	Clynes et al., Science 279:1052-1054, 1998
C30	de Haas, Wien Kin Wochenscha 113:825-831, 2001
C31	Deisenhofer, Biochem. 20:2361-2370, 1981
C32	Deo et al., Immunology Today 18:127-135, 1997
C33	Duncan and Winter, Nature 332 :738-740, 1988
C34	Duncan and Winter, Nature 332:563-564, 1988
C35	Flesch and Neppert, J Clin Lab Anal 14:144-156, 2000
C36	Gergeley et al., Biochemical Society Transactions 12:739-743, 1984
C37	Gergely and Sarmay, FASEB J 4:3275-3283, 1990
C38	Greenwood and Clark, Effector functions of matched sets of recombinant human IgG subclass antibodies. (final version edited Feb. 11, 1993)
C39	Greenwood et al., Eur J Immunol 23:1098-1104, 1993
C40	Greenwood et al., Therapeutic Immunology 1:247-255, 1994
C41	Hadley et al., Immunology 76:446-451, 1992
C42	Hatta et al., Genes and Immunity 1:53-60, 1999
C43	Hayes, Fc Engineering to Enhance Monoclonal Antibody Effector Functions. (Presentation) Xecor, CA, 2003
C44	Herzenberg et al., Clinical Chem. 2002:48:1819-1827, 2002
C45	Heyman, Annu Rev Immunol 18:709-737, 2000
C46	Hogarth et al., Immunomethods 4 :17-24, 1994
C47	Holler et al., PNAS 97 :5387-92, 2000
C48	Hulett et al., J. Biol. Chem. 269:15287-15293, 1994
C49	Hulett et al., J. Biol. Chem. 270:21188-21194, 1995
C50	Hulett et al., J Immunol 147 :1863-1868, 1991

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<i>Substitute for Form 1449A</i> LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11183-004-999	10/754,922
	APPLICANT	
	Stavnhagen et al.	
	FILING DATE	ART UNIT
	January 9, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C51	Idusogie et al., J Immunol 164: 4178-4184, 2000
C52	Idusogie et al., J Immunol 166 :2571-2575, 2001
C53	Isaacs et al., Clin Exp Immunol 106 :427-433, 1996
C54	Isaacs et al., J Immunol 148 :3062-3071, 1992
C55	Isaacs et al., J Immunol 161 :3862-3869, 1998
C56	Jassal et al., Biochem Soc Trans 26 :S113, 1998
C57	Jefferis and Lund, Immunology Letters 82 :57-65, 2002
C58	Jefferis et al., Immunol Lett 44 :111-7, 1995
C59	Jefferis et al., Immunol Rev 163:59-76, 1998
C60	Jefferis et al., Mol Immunol 27 :1237-1240, 1990
C61	Jendeberg et al., J Immunological Methods 201 :25-34, 1997
C62	Kadar et al., Immunol Lett 32:59-63, 1992
C63	Kadar et al., Int J Immunopharmacol 13 :1147-55, 1991
C64	Kato et al., J Mol Biol 295:213-224, 2000
C65	Keler et al., J. of Immunol. 164:5746-52, 2000
C66	Kieke et al., PNAS 96 :5651-56, 1999
C67	Kim et al., J Mol Evol 53:1-9, 2001
C68	Klein et al., PNAS 78 :524-528, 1981
C69	Koene et al., Blood 90 :1109-1114, 1997
C70	Kranz et al., J. Biol. Chem. 257:6987-6995, 1982
C71	Lehmann et al., J Immunol Methods. 243(1-2):229-42, 2000
C72	Lehrnbecher et al., Blood 94:4220-4232, 1999
C73	Li et al., J Exp Med 183 :1259-1263, 1996
C74	Liu et al., J. Immunol. 139:3521-3526, 1987
C75	Lund et al., Eur J Biochem 267 :7246-57, 2000
C76	Lund et al., FASEB J 9 :115-119, 1995
C77	Lund et al., J Immunol 147 :2657-62, 1991
C78	Lund et al., J Immunol 157 :4963-4969, 1996
C79	Lund et al., Molecular Immunology 29:53-59, 1992
C80	Maenaka et al., J Biol Chem 48 :44898-904, 2001
C81	Michaelsen et al., Immunolgy 91 :9243-9247, 1994

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

11183-004-999

APPLICATION NO.

10/754,922

APPLICANT

Stavenhagen et al.

FILING DATE

January 9, 2004

ART UNIT

1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C82	Morgan et al., Immunology 86 :319-324, 1995
C83	Morrison et al., Immunologist 2 :119-124, 1994
C84	Munn et al., J Exp Med. 172(1):231-7, 1990
C85	Nagarajan et al., J Biol Chem 270 :25762-25770, 1995
C86	Neuberger et al., Nature 312 :604-608, 1984
C87	Norderhaug et al., Eur J Immunol 21:2379-84, 1991
C88	Nose and Leanderson, Eur J Immunol 19 :2179-81, 1989
C89	Okazaki et al., J Mol Biol 336 :1239-1249, 2004
C90	Orfao and Ruiz-Arguelles, Clinical Biochem. 29:5-9, 1996
C91	Partridge et al., Mol Immunol. 23(12):1365-72, 1986
C92	Perussia "Human Natural Killer Cell Protocols" in <i>Methods Molecular Biology</i> . vol. 121 (Campbell et al. eds.) Humana Press Inc., Totowa, NJ. 179-92, 2000
C93	Radaev and Sun, Molecular Immunology 38 :1073-1083, 2001
C94	Ravetch and Bolland, Annu Rev Immunol 19:275-90, 2001
C95	Ravetch and Clynes, Annu Rev Immunol 16:421-432, 1998
C96	Ravetch and Kinet, Annu Rev Immunol 9:457-492, 1991
C97	Ravetch and Lanier, Science 290:84-89, 2000
C98	Redpath et al., Hum Immunol 59 :720-727, 1998
C99	Reff et al., Blood 83:435-445, 1994
C100	Riechmann et al., Nature. 332(6162):323-7, 1988
C101	Sarmay et al., Eur J Immunol 18 :289-294, 1988
C102	Sarmay et al., Mol Immunol 21 :43-51, 1984
C103	Sarmay et al., Mol Immunol 29 :633-639, 1992
C104	Sautes-Fridman et al., ASHI Quarterley, 4 th Quarter:148-151, 2003
C105	Schaffner et al., Mol Immunol 32 :9-20, 1995 (Erratum in 32 :1299, 1995)
C106	Schatz et al., Bio/Technology 11:1138-1143, 2000
C107	Sensel et al., Molecular Immunology 34:1019-1029, 1997
C108	Shields et al., J Biol Chem 276 :6591-6604, 2001
C109	Shopes et al., J Immunol 145 :3842-3848, 1990
C110	Shopes, J Immunol 148 :2918-2922, 1992
C111	Shopes, Molecular Immunology 30 :603-609, 1993

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

11183-004-999

APPLICATION NO.

10/754,922

APPLICANT

Stavnhagen et al.

FILING DATE

January 9, 2004

ART UNIT

1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C112	Shusta et al., J Mol Biol 292:949-956, 1999
C113	Shusta et al., Nature Biotechnology 16:773-777, 1998
C114	Shusta et al., Nature Biotechnology 18:754-759, 2000
C115	Smith and Morrison, Bio/Technology 12:683-688, 1994
C116	Sondermann and Oosthuizen, Immunology Letters, 82:51-56, 2002
C117	Sondermann et al., J. Mol. Biol. 309:737-749, 2001
C118	Sondermann et al., EMBO J 18:1095-1103, 1999
C119	Sondermann et al., Nature 406:267-273, 2000
C120	Steplewski et al., PNAS 85:4852-4856, 1988
C121	Strohmeier et al., J Leukocyte Biol 58:415-422, 1995
C122	Sylvestre and Ravetch, Immunity 5:387-390, 1996
C123	Sylvestre and Ravetch, Science 265:1095-1098, 1994
C124	Takai et al., Cell 76 :519-529, 1994
C125	Takai et al., Nature 379:346-349, 1996
C126	Takai, Nature Reviews 2:580-592, 2002
C127	Tamm et al., J Biol Chem 271:3659-3666, 1996
C128	Tao et al., J Exp Med 173:1025-1028, 1991
C129	Tao et al., J Exp Med 178:661-667, 1993
C130	Van Sorge et al., Tissue Antigens 61:189-202, 2003
C131	VanAntwerp and Wittrup, Biotechnol Prog 16:31-37, 2000
C132	Vidarte, J Biol Chem 276:38217-38233, 2001
C133	Ward and Ghetie, Therapeutic Immunology 2:77-94, 1995
C134	Weng and Levy J Clin Oncol 21:3940-3947, 2003
C135	Wing et al., J Clin Invest 98 :2819-2826, 1996
C136	Wingren et al., Scand J Immunol 44:430-436, 1996
C137	Wittrup, Nat Biotechnol 18:1039-1040, 2000
C138	Wittrup, Curr, Opin. Biotechnol. 12:395-399, 2001
C139	Woo et al., Mol Immunol 23 :319-330, 1986
C140	Wu et al., J Clin Invest 100 :1059-1070, 1997
C141	Xu et al., J Biol Chem 269 :3469-3474, 1994
C142	Yeung and Wittrup, Biotechnol Prog 18:212-220, 2002

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail. No. EV 654 849 595 US
Sheet 8 of 8 of List of References

Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

11183-004-999

APPLICATION NO.

10/754,922

APPLICANT

Stavenhagen et al.

FILING DATE

January 9, 2004

ART UNIT

1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C143 Zeidler et al., British J Cancer 83:261-266, 2000

C144 Zuckier et al., Cancer Res 58 :3905-3908, 1998

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYJD: 1615621.4

Substitute PTO/SB/08a / PTO/SB/08b				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/754,922
				Filing Date	January 9, 2004
				First Named Inventor	STAVENHAGEN, Jeffrey
				Art Unit	1643 1644
				Examiner Name	CROWDER, Chun
Sheet	1	of	9	Attorney Docket Number	1301.0004C

U.S. PATENT DOCUMENTS					
Examiner's Initial	Cite No.	Document Number Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner's Initial	Cite No.	Foreign Patent Document Country Code-Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

NON-PATENT LITERATURE DOCUMENTS					
Examiner's Initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city, and/or country where published			T
/CC/	C01	Altman <i>et al.</i> , Phenotypic Analysis of Antigen-Specific T Lymphocytes", Science 274:94-96, 1996			
	C02	Angal <i>et al.</i> , "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody," Mol Immunol 30 :105-108, 1993			
	C03	Armour <i>et al.</i> , "The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors," Biochemical Society Transactions 30:495-500, 2002			
	C04	Armour <i>et al.</i> , "Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities," Eur J Immunol 29:2613-2624, 1999			
	C05	Armour <i>et al.</i> , "Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies," Mol Immunol 40 :585-593, 2003			
	C145	Armstrong, S. <i>et al.</i> "Heterogeneity of IgG1 monoclonal anti-Rh(D): an investigation using ADCC and macrophage binding assays," Brit. J. Haematol. 66:257-262 (1987)			
	C06	Baggiolini M, Dewald B. "Cellular models for the detection and evaluation of drugs that modulate human phagocyte activity," Experientia. Oct 15;44(10):841-848, 1988			
	C07	Boder and Wittrup, 1997, "Yeast surface display for screening combinatorial polypeptide libraries", Nature Biotechnology 15:553-557			
	C08	Boder and Wittrup, "Optimal screening of surface-displayed polypeptide libraries," Biotechnol Prog 14:55-62, 1998			
/CC/	C09	Boder and Wittrup, "Yeast surface display for directed evolution of protein expression, affinity, and stability," Methods in Enzymology 328:430-444, 2000			

Examiner Signature	/Chun Crowder/ (04/12/2007)	Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

Substitute PTO/SB/08a / PTO/SB/08b				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/754,922
				Filing Date	January 9, 2004
				First Named Inventor	STAVENHAGEN, Jeffrey
				Art Unit	1043 1644
				Examiner Name	CROWDER, Chun
Sheet	2	of	9	Attorney Docket Number	1301.0004C

/CCI/	C10	Boder <i>et al.</i> , "Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity," Proc. Natl. Acad. Sci. USA 97:10701-10705, 2000	
	C11	Bredius <i>et al.</i> , "Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes," Immunology 83:624-630, 1994	
	C12	Brekke <i>et al.</i> , "Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis," Eur J Immunol 24:2542-2547, 1994	
	C13	Brown EJ, Vol. 45 (Microbes as Tools for Cell Biology) in <i>Methods In Cell Biology</i> , Russell ed. Academic Press Inc. pp.147-64, 1994	
	C14	Burlmeister <i>et al.</i> , "Crystal structure of the complex of rat neonatal Fc receptor with Fc," Nature 372:379-383, 1994	
	C15	Burton and Woof, "Human antibody effector function," Advances in Immunology 51:1-84, 1992	
	C16	Burton <i>et al.</i> , "Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI)," Mol Immunol 25:1175-1181, 1988	
	C17	Burton, "Immunoglobulin G: functional sites," Mol Immunol 22:161-206, 1985	
	C18	Canfield and Morrison, "The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region," J Exp Med 173:1483-1491, 1991	
	C19	Caron <i>et al.</i> , "Engineered humanized dimeric forms of IgG are more effective antibodies," J Exp Med 176 :1191-5, 1992	
	C20	Carter <i>et al.</i> , "Humanization of an anti-p185HER2 antibody for human cancer therapy," Proc. Natl. Acad. Sci. USA 89:4285-4289, 1992	
	C21	Cartron <i>et al.</i> , "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIa gene," Blood 99 :754-758, 2002	
	C22	Chappel <i>et al.</i> , "Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies," Proc. Natl. Acad. Sci USA 88:9036-9040, 1991	
	C23	Chappel <i>et al.</i> , "Identification of a secondary Fc gamma RI binding site within a genetically engineered human IgG antibody," J Biol. Chem 268:25124-25131, 1993	
	C24	Ciccimarra <i>et al.</i> , "Localization of the IgG effector site for monocyte receptors," Proc. Natl. Acad. Sci. U.S.A. 72 :2081-2083, 1975	
	C25	Clynes and Ravetch, "Cytotoxic antibodies trigger inflammation through Fc receptors," Immunity 3:21-26, 1995	
	C26	Clynes <i>et al.</i> , "Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors," J Exp Med 189:179-185, 1999	
/CCI/	C27	Clynes <i>et al.</i> , "Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets," Nature Medicine 6 :443-446, 2000	

Examiner Signature	/Chun Crowder/ (04/12/2007)	Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

Substitute PTO/SB/08a / PTO/SB/08b				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/754,922
				Filing Date	January 9, 2004
				First Named Inventor	STAVENHAGEN, Jeffrey
				Art Unit	1049 1644
				Examiner Name	CROWDER, Chun
Sheet	3	of	9	Attorney Docket Number	1301.0004C

/CCI/	C28	Clynes <i>et al.</i> , "Fc receptors are required in passive and active immunity to melanoma," Proc. Natl. Acad. Sci USA 95:652-656, 1998	
	C29	Clynes <i>et al.</i> , "Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis," Science 279:1052-1054, 1998	
	C30	de Haas, Wien Kin "IgG-Fc receptors and the clinical relevance of their polymorphisms," Wien Klin Wochenscha 113:825-831, 2001	
	C31	Deisenhofer, "Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution," Biochem. 20:2361-2370, 1981	
	C32	Deo <i>et al.</i> , "Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies," Immunology Today 18:127-135, 1997	
	C33	Duncan and Winter, "The binding site for C1q on IgG," Nature 332 :738-740, 1988	
	C34	Duncan and Winter, "Localization of the binding site for the human high-affinity Fc receptor on IgG," Nature 332:563-564, 1988	
	C35	Flesch and Neppert, "Functions of the Fc receptors for immunoglobulin G," J Clin Lab Anal 14:141-156, 2000	
	C36	Gergeley <i>et al.</i> , "Fc receptors on lymphocytes and K cells," Biochemical Society Transactions 12:739-743, 1984	
	C37	Gergely and Sarmay, "The two binding-site models of human IgG binding Fc gamma receptors," FASEB J 4:3275-3283, 1990	
	C38	Greenwood and Clark, Effector functions of matched sets of recombinant human IgG subclass antibodies". (final version edited Feb. 11, 1993)	
	C39	Greenwood <i>et al.</i> , "Structural motifs involved in human IgG antibody effector functions," Eur J Immunol 23:1098-1104, 1993	
	C40	Greenwood <i>et al.</i> , "Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis," Therapeutic Immunology 1:247-255, 1994	
	C41	Hadley <i>et al.</i> , "The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes," Immunology 76:446-451, 1992	
	C42	Hatta <i>et al.</i> , "Association of Fc gamma receptor IIIB, but not of Fc gamma receptor IIA and IIIA polymorphisms with systemic lupus erythematosus in Japanese," Genes and Immunity 1:53-60, 1999	
	C43	Hayes, Fc Engineering to Enhance Monoclonal Antibody Effector Functions. (Presentation) Xecor, CA, 2003	
	C44	Herzenberg <i>et al.</i> , "The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford," Clinical Chem. 2002:48:1819-1827, 2002	
/CCI/	C45	Heyman, "Regulation of antibody responses via antibodies, complement, and Fc receptors," Annu Rev Immunol 18:709-737, 2000	

Examiner Signature	/Chun Crowder/ (04/12/2007)	Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

Substitute PTO/SB/08a / PTO/SB/08b				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/754,922
				Filing Date	January 9, 2004
				First Named Inventor	STAVENHAGEN, Jeffrey
				Art Unit	1049 1644
				Examiner Name	CROWDER, Chun
Sheet	4	of	9	Attorney Docket Number	1301.0004C

/CC/	C46	Hogarth <i>et al.</i> , "Characterization of FcR Ig-binding sites and epitope mapping," Immunomethods 4 :17-24, 1994	
	C47	Holler <i>et al.</i> , "In vitro evolution of a T cell receptor with high affinity for peptide/MHC," Proc. Natl. Acad. Sci. U.S.A. 97 :5387-92, 2000	
	C48	Hulett <i>et al.</i> , "Identification of the IgG binding site of the human low affinity receptor for IgG Fc gamma RII. Enhancement and ablation of binding by site-directed mutagenesis," J. Biol. Chem. 269:15287-15293, 1994	
	C49	Hulett <i>et al.</i> , "Multiple regions of human Fc gamma RII (CD32) contribute to the binding of IgG," J. Biol. Chem. 270:21188-21194, 1995	
	C50	Hulett <i>et al.</i> , "Chimeric Fc receptors identify functional domains of the murine high affinity receptor for IgG," J Immunol 147 :1863-1868, 1991	
	C51	Idusogie <i>et al.</i> , "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," J Immunol 164: 4178-4184, 2000	
	C52	Idusogie <i>et al.</i> , "Engineered antibodies with increased activity to recruit complement," J Immunol 166 :2571-2575, 2001	
	C53	Isaacs <i>et al.</i> , "A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans," Clin Exp Immunol 106 :427-433, 1996	
	C54	Isaacs <i>et al.</i> , "Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential," J Immunol 148 :3062-3071, 1992	
	C55	Isaacs <i>et al.</i> , "Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function," J Immunol 161 :3862-3869, 1998	
	C56	Jassal <i>et al.</i> , "Remodeling glycans on IgG by genetic re-engineering," Biochem Soc Trans 26 :S113, 1998	
	C57	Jefferis and Lund, "Interaction sites on human IgG-Fc for Fc gamma R: current models," Immunology Letters 82 :57-65, 2002	
	C58	Jefferis <i>et al.</i> , "Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation," Immunol Lett 44 :111-7, 1995	
	C59	Jefferis <i>et al.</i> , "IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation," Immunol Rev 163:59-76, 1998	
	C60	Jefferis <i>et al.</i> , "Molecular definition of interaction sites on human IgG for Fc receptors (huFc gamma R)," Mol Immunol 27 :1237-1240, 1990	
	C61	Jendeberg <i>et al.</i> , "Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A," J Immunological Methods 201 :25-34, 1997	
/CC/	C62	Kadar <i>et al.</i> , "Synthetic peptides comprising defined sequences of CH-2 and CH-3 domains of human IgG1 induce prostaglandin E2 production from human peripheral blood mononuclear cells," Immunol Lett 32:59-63, 1992	

Examiner Signature	/Chun Crowder/ (04/12/2007)	Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

Substitute PTO/SB/08a / PTO/SB/08b				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/754,922
				Filing Date	January 9, 2004
				First Named Inventor	STAVENHAGEN, Jeffrey
				Art Unit	1049 1644
				Examiner Name	CROWDER, Chun
Sheet	5	of	9	Attorney Docket Number	1301.0004C

/CC/	C63	Kadar <i>et al.</i> , "Modulatory effect of synthetic human IgG Fc peptides on the in vitro immune response of murine spleen cells," Int J Immunopharmacol 13 :1147-55, 1991	
	C64	Kato <i>et al.</i> , "Structural basis of the interaction between IgG and Fcγ receptors," J Mol Biol 295:213-224, 2000	
	C65	Keler <i>et al.</i> , "Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages," J. of Immunol. 164:5746-52, 2000	
	C66	Kieke <i>et al.</i> , "Selection of functional T cell receptor mutants from a yeast surface-display library," Proc. Natl. Acad. Sci. U.S.A. 96 :5651-56, 1999	
	C67	Kim <i>et al.</i> , "Analysis of FcγRIII and IgG Fc polymorphism reveals functional and evolutionary implications of protein-protein interaction," J Mol Evol 53:1-9, 2001	
	C68	Klein <i>et al.</i> , "Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region," Proc. Natl. Acad. Sci. U.S.A. 78 :524-528, 1981	
	C69	Koene <i>et al.</i> , "Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype," Blood 90 :1109-1114, 1997	
	C70	Kranz <i>et al.</i> , "Mechanisms of ligand binding by monoclonal anti-fluorescyl antibodies," J. Biol. Chem. 257:6987-6995, 1982	
	C146	Kumpel, B.M. Brit. "Human monoclonal anti-D antibodies," J. Haematol. 71:415-420 (1989)	
	C71	Lehmann <i>et al.</i> , "Phagocytosis: measurement by flow cytometry," J Immunol Methods. 243(1-2):229-42, 2000	
	C72	Lehrnbecher <i>et al.</i> , "Variant genotypes of the low-affinity Fcγgamma receptors in two control populations and a review of low-affinity Fcγgamma receptor polymorphisms in control and disease populations," Blood 94:4220-4232, 1999	
	C73	Li <i>et al.</i> , "Reconstitution of human Fc gamma RIII cell type specificity in transgenic mice," J Exp Med 183 :1259-1263, 1996	
	C74	Liu <i>et al.</i> , "Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity," J. Immunol. 139:3521-3526, 1987	
	C75	Lund <i>et al.</i> , "Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcγgamma receptor I," Eur J Biochem 267 :7246-57, 2000	
	C76	Lund <i>et al.</i> , "Oligosaccharide-protein interactions in IgG can modulate recognition by Fc gamma receptors," FASEB J 9 :115-119, 1995	
	C77	Lund <i>et al.</i> , "Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG," J Immunol 147 :2657-62, 1991	
/CC/	C78	Lund <i>et al.</i> , "Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains," J Immunol 157 :4963-4969, 1996	

Examiner Signature	/Chun Crowder/ (04/12/2007)	Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

Substitute PTO/SB/08a / PTO/SB/08b				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/754,922
				Filing Date	January 9, 2004
				First Named Inventor	STAVENHAGEN, Jeffrey
				Art Unit	1643 1644
				Examiner Name	CROWDER, Chun
Sheet	6	of	9	Attorney Docket Number	1301.0004C

/CC/	C79	Lund <i>et al.</i> , "Multiple binding sites on the CH2 domain of IgG for mouse Fc gamma R11," Molecular Immunology 29:53-59, 1992	
	C80	Maenaka <i>et al.</i> , "The human low affinity Fc gamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties," J Biol Chem 48 :44898-904, 2001	
	C81	Michaelsen <i>et al.</i> , "One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge," Immunology 91 :9243-9247, 1994	
	C82	Morgan <i>et al.</i> , "The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding," Immunology 86 :319-324, 1995	
	C83	Morrison <i>et al.</i> , "Structural determinants of IgG structure," Immunologist 2 :119-124, 1994	
	C84	Munn <i>et al.</i> , "Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor," J Exp Med. 172(1):231-7, 1990	
	C85	Nagarajan <i>et al.</i> , "Ligand binding and phagocytosis by CD16 (Fc gamma receptor III) isoforms. Phagocytic signaling by associated zeta and gamma subunits in Chinese hamster ovary cells," J Biol Chem 270 :25762-25770, 1995	
	C86	Neuberger <i>et al.</i> , "Recombinant antibodies possessing novel effector functions," Nature 312 :604-608, 1984	
	C87	Norderhaug <i>et al.</i> , "Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge," Eur J Immunol 21:2379-84, 1991	
	C88	Nose and Leanderson, "Substitution of asparagine324 with aspartic acid in the Fc portion of mouse antibodies reduces their capacity for C1q binding," Eur J Immunol 19 :2179-81, 1989	
	C89	Okazaki <i>et al.</i> , "Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and Fc gamma RIIIa," J Mol Biol 336 :1239-1249, 2004	
	C90	Orfao and Ruiz-Arguelles, "General concepts about cell sorting techniques," Clinical Biochem. 29:5-9, 1996	
	C91	Partridge <i>et al.</i> , "The use of anti-IgG monoclonal antibodies in mapping the monocyte receptor site on IgG," Mol Immunol. 23(12):1365-72, 1986	
	C92	Perussia "Human Natural Killer Cell Protocols" in <i>Methods Molecular Biology</i> . vol. 121 (Campbell <i>et al.</i> eds.) Humana Press Inc., Totowa, NJ. 179-92, 2000	
	C93	Radaev and Sun, "Recognition of immunoglobulins by Fc gamma receptors," Molecular Immunology 38 :1073-1083, 2001	
	C94	Ravetch and Bolland, "IgG Fc receptors," Annu Rev Immunol 19:275-90, 2001	
	C95	Ravetch and Clynes, "Divergent roles for Fc receptors and complement in vivo," Annu Rev Immunol 16:421-432, 1998	
/CC/	C96	Ravetch and Kinet, "Fc receptors," Annu Rev Immunol 9:457-492, 1991	

Examiner Signature	/Chun Crowder/ (04/12/2007)	Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

Substitute PTO/SB/08a / PTO/SB/08b				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/754,922
				Filing Date	January 9, 2004
				First Named Inventor	STAVENHAGEN, Jeffrey
				Art Unit	4643 1644
				Examiner Name	CROWDER, Chun
Sheet	7	of	9	Attorney Docket Number	1301.0004C

/CC/	C97	Ravetech and Lanier, "Immune inhibitory receptors," Science 290:84-89, 2000	
	C98	Redpath <i>et al.</i> , "The influence of the hinge region length in binding of human IgG to human Fc gamma receptors," Hum Immunol 59 :720-727, 1998	
	C99	Reff <i>et al.</i> , "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," Blood 83:435-445, 1994	
	C100	Riechmann <i>et al.</i> , "Reshaping human antibodies for therapy," Nature. 332(6162):323-7, 1988	
	C101	Sarmay <i>et al.</i> , "The effect of synthetic peptides corresponding to Fc sequences in human IgG1 on various steps in the B cell activation pathway," Eur J Immunol 18 :289-294, 1988	
	C102	Sarmay <i>et al.</i> , "Ligand inhibition studies on the role of Fc receptors in antibody-dependent cell-mediated cytotoxicity," Mol Immunol 21 :43-51, 1984	
	C103	Sarmay <i>et al.</i> , "Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc gamma receptor," Mol Immunol 29 :633-639, 1992	
	C104	Sautes-Fridman <i>et al.</i> , "Fc gamma receptors: a magic link with the outside world," ASHI Quarterley, 4 th Quarter:148-151, 2003	
	C105	Schaffner <i>et al.</i> , "Chimeric interleukin 2 receptor alpha chain antibody derivatives with fused mu and gamma chains permit improved recruitment of effector functions," Mol Immunol 32 :9-20, 1995 (Erratum in 32 :1299, 1995)	
	C106	Schatz <i>et al.</i> , "Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in Escherichia coli," Bio/Technology 11:1138-1143, 2000	
	C107	Sensel <i>et al.</i> , "Amino acid differences in the N-terminus of C(H)2 influence the relative abilities of IgG2 and IgG3 to activate complement," Molecular Immunology 34:1019-1029, 1997	
	C108	Shields <i>et al.</i> , "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R," J Biol Chem 276 :6591-6604, 2001	
	C109	Shopes <i>et al.</i> , "Recombinant human IgG1-murine IgE chimeric Ig. Construction, expression, and binding to human Fc gamma receptors," J Immunol 145 :3842-3848, 1990	
	C110	Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity," J Immunol 148 :2918-2922, 1992	
	C111	Shopes, "A genetically engineered human IgG with limited flexibility fully initiates cytolysis via complement," Molecular Immunology 30 :603-609, 1993	
	C112	Shusta <i>et al.</i> , "Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency," J Mol Biol 292:949-956, 1999	
/CC/	C113	Shusta <i>et al.</i> , "Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments," Nature Biotechnology 16:773-777, 1998	

Examiner Signature	/Chun Crowder/ (04/12/2007)	Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

Substitute PTO/SB/08a / PTO/SB/08b				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/754,922
				Filing Date	January 9, 2004
				First Named Inventor	STAVENHAGEN, Jeffrey
				Art Unit	1643 1644
				Examiner Name	CROWDER, Chun
Sheet	8	of	9	Attorney Docket Number	1301.0004C

/CC/	C114	Shusta <i>et al.</i> , "Directed evolution of a stable scaffold for T-cell receptor engineering," Nature Biotechnology 18:754-759, 2000	
	C115	Smith and Morrison, "Recombinant polymeric IgG: an approach to engineering more potent antibodies," Bio/Technology 12:683-688, 1994	
	C116	Sondermann and Oosthuizen, "The structure of Fc receptor/Ig complexes: considerations on stoichiometry and potential inhibitors," Immunology Letters, 82:51-56, 2002	
	C117	Sondermann <i>et al.</i> , "Molecular basis for immune complex recognition: a comparison of Fc-receptor structures," J. Mol. Biol. 309:737-749, 2001	
	C118	Sondermann <i>et al.</i> , "Crystal structure of the soluble form of the human fcgamma-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution," EMBO J 18:1095-1103, 1999	
	C119	Sondermann <i>et al.</i> , "The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex," Nature 406:267-273, 2000	
	C120	Stepleski <i>et al.</i> , "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity," Proc. Natl. Acad. Sci. U.S.A. 85:4852-4856, 1988	
	C121	Strohmeier <i>et al.</i> , "Role of the Fc gamma R subclasses Fc gamma RII and Fc gamma RIII in the activation of human neutrophils by low and high valency immune complexes," J Leukocyte Biol 58:415-422, 1995	
	C122	Sylvestre and Ravetch, "A dominant role for mast cell Fc receptors in the Arthus reaction," Immunity 5:387-390, 1996	
	C123	Sylvestre and Ravetch, "Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade," Science 265:1095-1098, 1994	
	C124	Takai <i>et al.</i> , "FcR gamma chain deletion results in pleiotrophic effector cell defects," Cell 76 :519-529, 1994	
	C125	Takai <i>et al.</i> , "Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice," Nature 379:346-349, 1996	
	C126	Takai, "Roles of Fc receptors in autoimmunity," Nature Reviews 2:580-592, 2002	
	C127	Tamm <i>et al.</i> , "The IgG binding site of human FcγRIIIB receptor involves CC' and FG loops of the membrane-proximal domain," J Biol Chem 271:3659-3666, 1996	
	C128	Tao <i>et al.</i> , "The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain," J Exp Med 173:1025-1028, 1991	
	C129	Tao <i>et al.</i> , "Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation," J Exp Med 178:661-667, 1993	
	C130	Van Sorge <i>et al.</i> , "FcγgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy," Tissue Antigens 61:189-202, 2003	
/CC/	C131	VanAntwerp and Wittrup, "Fine affinity discrimination by yeast surface display and flow cytometry," Biotechnol Prog 16:31-37, 2000	

Examiner Signature	/Chun Crowder/ (04/12/2007)	Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

Substitute PTO/SB/08a / PTO/SB/08b				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/754,922
				Filing Date	January 9, 2004
				First Named Inventor	STAVENHAGEN, Jeffrey
				Art Unit	1643 1644
				Examiner Name	CROWDER, Chun
Sheet	9	of	9	Attorney Docket Number	1301.0004C

/CC/	C132	Vidarte, "Serine 132 is the C3 covalent attachment point on the CH1 domain of human IgG1," J Biol Chem 276:38217-38233, 2001	
	C133	Ward and Ghetie, "The effector functions of immunoglobulins: implications for therapy," Therapeutic Immunology 2:77-94, 1995	
	C134	Weng and Levy, "Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma," J Clin Oncol 21:3940-3947, 2003	
	C147	Wiener, E. <i>et al.</i> "Differences between the activities of human monoclonal IgG1 and IgG3 anti-D antibodies of the Rh blood group system in their abilities to mediate effector functions of monocytes," Immunol. 65:159-163 (1988)	
	C135	Wing <i>et al.</i> , "Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells," J Clin Invest 98 :2819-2826, 1996	
	C136	Wingren <i>et al.</i> , "Comparison of surface properties of human IgA, IgE, IgG and IgM antibodies with identical and different specificities," Scand J Immunol 44:430-436, 1996	
	C137	Wittrup, "The single cell as a microplate well," Nat Biotechnol 18:1039-1040, 2000	
	C138	Wittrup, "Protein engineering by cell-surface display," Curr, Opin. Biotechnol. 12:395-399, 2001	
	C139	Woof <i>et al.</i> , "Localisation of the monocyte-binding region on human immunoglobulin G," Mol Immunol 23 :319-330, 1986	
	C140	Wu <i>et al.</i> , "a novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease," J Clin Invest 100 :1059-1070, 1997	
	C141	Xu <i>et al.</i> , "Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement," J Biol Chem 269 :3469-3474, 1994	
	C142	Yeung and Wittrup, "Quantitative screening of yeast surface-displayed polypeptide libraries by magnetic bead capture," Biotechnol Prog 18:212-220, 2002	
	C143	Zeidler <i>et al.</i> , "The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells," British J Cancer 83:261-266, 2000	
/CC/	C144	Zuckier <i>et al.</i> , "Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life," Cancer Res 58 :3905-3908, 1998	

Examiner Signature	/Chun Crowder/ (04/12/2007)	Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			